Supplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers | Synapse
September 16, 2024
Supplementary Fig.S1 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Key Points
Key points are not available for this paper at this time.
Abstract
Structure of linker-payload complexes and conjugation process of 9MW2821.